PALB2 and non-small cell lung carcinoma: PALB2 has been explored in the field of chemotherapy, and the presence of PALB2 mutation has been reported to be correlated with improved clinical outcomes in non-small cell lung cancer (NSCLC) treated with platinum-based chemotherapy (10).